Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
With over a decade of experience in phage display technology, Creative Biolabs can provide a series of antibody or peptide libraries that are available for licensing or direct screening. These ready-to-use libraries are invaluable resources for isolating target-specific binders for various research, diagnostic or therapeutic applications.
Creative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents. These cutting-edge technologies enable our scientists to meet your demands from different aspects and tailor the most appropriate solution that contributes to the success of your projects.
With deep understanding in antibody-related realms and extensive project experience, Creative Biolabs offers a variety of references to help you learn more about our capacities and achievements, including infographic, flyer, case study, peer-reviewed publications, and all kinds of knowledge that can assist your projects. You are also welcome to contact us directly for more specific solutions.
Get a real taste of Creative Biolabs, one of the most professional custom service providers in the world. We are committed to providing highly customized comprehensive solutions with the best quality to advance your projects.
Recombinant monoclonal antibody to CTLA4. Tremelimumab (formerly ticilimumab, CP-675,206) is a fully human IgG2 monoclonal antibody, undergoing human trials for the treatment of cancer.
Target
CTLA4
Type
IgG2
Immunogen
Human CTLA-4.
Species Reactivity
Human
Expression Host
CHO
Applications
Suitable for use in FC, IP, ELISA, Neut, FuncS, IF, WB and most other immunological methods.
CAS
745013-59-6
Specific Activity
Tested positive against native human antigen.
Protein Construction
Immunoglobulin G2,anti-(human CTLA-4 (antigen)) (human monoclonal CP-675206 clone 11.2.1 heavychain) disulfide with human monoclonal CP-675206 clone 11.2.1 light chain,dimer
Molecular Weight
146400
Purity
>95%, by SDS-PAGE with silver staining, under reducing conditions.
Size
1mg
Storage
Store at 4°C for up to 3 months. For longer term storage aliquot into small volumes and store at -20°C.
BACKGROUND
Antigen Description
Inhibitory receptor acting as a major negative regulator of T-cell responses. The affinity of CTLA4 for its natural B7 family ligands, CD80 and CD86, is considerably stronger than the affinity of their cognate stimulatory coreceptor CD28.